| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on October 23, 2002
From the Department of Medicine, Division of Hypertension, Case Western Reserve University (M.V., Z.-J.C., D.C., S.L., C.-H.C.), Cleveland, Ohio; the Department of Medicine, Reproductive Research Center, Shandong Provincial Hospital, Shandong University (Z.-J.C.), Jinan, Peoples Republic of China; and the Graduate Institute of Biological Sciences, National Taiwan University (G.-D.C.), Taipei, Taiwan. * To whom correspondence should be addressed. E-mail: cxc13{at}po.cwru.edu.
Abstract--Cyclosporin A (CsA) is used to reduce transplant rejection rates. Chronic use, however, has a destructive toxic effect on the kidney, resulting in hypertension. In this study, we investigated the effects of CsA treatment on the bradykinin/soluble guanylate cyclase signaling cascade and the involvement of superoxide in LLC-PK1 porcine kidney proximal tubule cells. Treatment with 1 µmol/L CsA for 24 hours increased basal cGMP levels by 41%, whereas CsA inhibited bradykinin-stimulated cGMP production by 26%. Western blotting showed increased expression of eNOS, but no other protein in the bradykinin/soluble guanylate cyclase (sGC) pathway was affected. Using lucigenin-dependent chemiluminescence, we found that CsA treatment significantly increased superoxide production. Production of O2- was not significantly reduced by 10 µmol/L oxypurinol or 30 µmol/L ketoconazole. However, it was inhibited by the NADPH oxidase inhibitor diphenyleneiodonium chloride (10 µmol/L) as well as the O2- scavenger superoxide dismutase (SOD) (100 U). On treatment with 50 µmol/L quercetin, 10 mmol/L N-acetyl-cysteine, both antioxidants, as well as the O2- scavenger Tiron (10 mmol/L), concomitant with 1 µmol/L CsA for 24 hours the activation of cGMP production, was restored in combination with a reduction in O2-. Incubation with 100 µmol/L menadione, a reactive oxygen generator, and 10 nmol/L bradykinin showed similar effects on the level of cGMP as with CsA. CsA treatment was found to increase nitrotyrosine levels. These findings suggest that CsA activates a NADPH oxidase that releases O2- and disrupts the bradykinin/soluble guanylate cyclase pathway, probably by binding with NO to form peroxynitrite (ONOO-).
Revised on November 12, 2002
Cyclosporin A Disrupts Bradykinin Signaling Through Superoxide
Michael Vetter;
This article has been cited by other articles:
![]() |
A. K. Khanna and G. M. Pieper NADPH oxidase subunits (NOX-1, p22phox, Rac-1) and tacrolimus-induced nephrotoxicity in a rat renal transplant model Nephrol. Dial. Transplant., February 1, 2007; 22(2): 376 - 385. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-J. Chen, M. Vetter, G.-D. Chang, S. Liu, D. Che, Y. Ding, S. S. Kim, and C.-H. Chang Cyclophilin A Functions as an Endogenous Inhibitor for Membrane-Bound Guanylate Cyclase-A Hypertension, December 1, 2004; 44(6): 963 - 968. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |